By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Rhythm 

500 Boylston Street, 11th Floor

Boston  Massachusetts  02116  U.S.A.
Phone: 857-264-4280 Fax: 857-264-4299


SEARCH JOBS

Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class melanocortin-4 (MC4) receptor agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project(www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, Massachusetts.

YEAR FOUNDED:

1956

LEADERSHIP:

Founder: Bart Henderson

CEO: Keith M. Gottesdiener

CMO: Fred T. Fiedorek

CSO: Lex H.T. Van der Ploeg

JOBS:

Please click here for.

CLINICAL TRIAL:

Please click here for clinical trial information.


PRODUCTS:

blank

FOLLOW AMGEN:



Key Statistics


Email: info@rhythmtx.com
Ownership: Private

Web Site: Rhythm
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Rhythm Appoints Head Of Sanofi Genzyme (SNY), Dr. David Meeker, As Chairman Of Board Of Directors 4/11/2017 9:12:09 AM
Boston's Rhythm Closes $41 Million to Push Lead Peptide Therapy Into Phase III Trials 2/16/2017 6:55:25 AM
Rhythm Presents Positive Initial Data For Setmelanotide In LepR Deficiency Obesity 11/4/2016 10:26:26 AM
Rhythm Announces "The Genetic Obesity Project" To Expand Understanding Of Rare Genetic Disorders Of Obesity 7/27/2016 6:18:49 AM
Rhythm Announces The New England Journal of Medicine Publication Of Setmelanotide Phase 2 Data For Treatment Of POMC Deficiency Obesity 7/21/2016 6:31:10 AM
Rhythm Wins FDA Breakthrough Tag for Setmelanotide for the Treatment Of POMC Deficiency Obesity 1/7/2016 7:41:10 AM
Rhythm Receives Orphan Drug Designation For Setmelanotide For The Treatment Of Prader-Willi Syndrome 1/7/2016 7:36:39 AM
Rhythm And Camurus Announce License Agreement For Extended Release Fluidcrystal Setmelanotide 1/5/2016 6:38:11 AM
Rhythm Appoints David Meeker, MD, And David Mcgirr To Board Of Directors 12/16/2015 8:27:11 AM
Rhythm Presents Cardiovascular Safety Data From Phase 1b/2a Clinical Trials Of Setmelanotide In Obesity 11/6/2015 10:32:52 AM
12345
//-->